GBGiorgio Battista Boncoraglio

Giorgio Battista Boncoraglio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giorgio Battista Boncoraglio has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Jonathan Rosand

    Center for Genomic Medicine, MGH, Boston, MA, USA

    30 shared publications
  • Cathie Sudlow

    Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics (C.S.), University of Edinburgh, United Kingdom

    28 shared publications
  • Martin Dichgans

    From the Department of Clinical Neurosciences, Stroke Research Group (M.T., D.J.T., I.D.C., D.M.L.F., A.O.O., L.R.-J., H.S.M.), University of Cambridge, UK; Department of Cerebrovascular Diseases (G.B.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Institute for Stroke and Dementia Research (M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich; German Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for Systems Neurology ...

    28 shared publications
  • Pankaj Sharma

    Institute of Cardiovascular Research, Royal Holloway University of London, London, UK, and Ashford and St Peters Hospital, Surrey, UK

    28 shared publications
  • Rainer Malik

    Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

    25 shared publications
  • Christopher R. Levi

    Hunter New England Local Health District, New Lambton Heights, New South Wales, 2305, Australia

    22 shared publications

Latest Publications

  • Open Access

    ALIGNED Network for rare cerebrovascular diseases: methodology and preliminary results

    by Carolina De Toma, Antonella Potenza, Nicola Rifino, Camilla Strazzabosco, Benedetta Storti, Giulia Marinoni, Tatiana Carrozzini, Gemma Gorla, Giuliana Pollaci, Elisabetta Pasella, et al.

    Introduction: Cerebrovascular diseases are a major cause of morbidity/mortality worldwide, yet more than 30% of strokes remain of undetermined origin. Rare cerebrovascular diseases (rCVDs) contribute to this burden but are often underdiagnosed due to limited awareness, clinical heterogeneity, and fragmented diagnostic access. The ALIGNED project was established to address these gaps through a nationwide multidisciplinary network. Methods: ALIGNED was aimed to improve clinical/molecular characterization of rCVDs through standardized data collection, assess level of care of rCVDs by an online/on-site survey and reduce the geographical gap across Italy, by a virtual model of rCVDs care. In the first phase we conducted a survey to evaluate the availability of diagnostic/therapeutic pathways. Preliminary molecular profiling (i.e., transcriptomic/proteomic analyses) has been carried out on middle-cerebral artery and plasma samples from Moyamoya angiopathy (MMA) patients. Results: Fourty-nine centers adhered to the project. Initially, we collected a cohort of 308 subjects with rCVDs: CADASIL (162), COL4A1/A2-related disease (9), Sneddon syndrome (25), Fabry disease (32), and MMA (80). Web-based survey and site visits provided a representative overview of national capabilities in rCVD diagnosis and care. Transcriptomic analysis showed a peculiar expression profile of angiogenesis growth factors/inhibitors in MMA cerebral vessels. Plasma proteomic profiles of MMA patients highlighted circulating proteins expressed in dysfunctional angiogenesis. Discussion: Preliminary data suggested a substantial variability in the quality of rCVDs management and in the availability of diagnostic tools across Italy. Thus, mapping Italian expertise and facilities emerged as a crucial target for pinpointing gaps, improving resource allocation, standardizing rCVD care to guarantee equitable access for patients.

  • Open Access

    Amyloid PET Burden, CSF Biomarkers, and APOE Genotype in People With Iatrogenic and Sporadic Cerebral Amyloid Angiopathy

    by Benedetta Storti, Antonella Capozza, Giulia Marinoni, Camilla Strazzabosco, Mario Stanziano, Nicola Rifino, Giorgio B. Boncoraglio, Irene Scala, Michele Romoli, Andrea Paccagnella, et al.

    Background and ObjectivesIatrogenic cerebral amyloid angiopathy (iCAA) is a rare form of CAA believed to result from β-amyloid (Aβ) transmission during neurosurgical procedures. We aimed to compare...


  • Open Access

    Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy With and Without Spontaneous Lobar Hemorrhage

    by Benedetta Storti, Giulia Marinoni, Benedetta Cefaloni, Alessandro Francia, Nicola Rifino, Giorgio Boncoraglio, Antonio Indaco, Giuseppe Di Fede, Mario Stanziano, Isabella Canavero, et al.

    Background: Cerebral amyloid angiopathy (CAA) typically presents as spontaneous lobar intracerebral hemorrhage (ICH) or cognitive impairment. While the Boston criteria 2.0 aid CAA diagnosis in ICH, detecting nonhemorrhagic cases remains challenging. Cerebrospinal fluid (CSF) biomarkers may offer valuable diagnostic support. This study aimed to evaluate CSF Aβ40, Aβ42, total‐τ, phosphorylated‐τ, Aβ42/Aβ40, and phosphorylated‐τ/Aβ42 in patients with CAA with and without symptomatic ICH. Methods: This prospective observational study recruited patients with CAA from the cerebrovascular clinic of Fondazione IRCCS Istituto Neurologico Carlo Besta (Milan, Italy) from January 2021 to June 2024. Patients underwent T2*‐weighted magnetic resonance imaging and lumbar puncture, with CSF biomarkers measured via Lumipulse. Participants were grouped into CAA−ICH+ (prior symptomatic lobar ICH) and CAA−ICH−. Results: Fifty‐four patients were included: 35 CAA−ICH+ (37.1% women) and 19 CAA−ICH− (52.4% men). Groups were similar in mean age at lumbar puncture (63.8 versus 67.9 years) and cognitive impairment prevalence (57.1% versus 47.4%). Median CSF Aβ40 level was significantly lower in CAA−ICH+ than in CAA−ICH− (4355 versus 6507 pg/mL, P P =0.09). Other CSF biomarkers levels were comparable between CAA−ICH+ and CAA−ICH−: total‐τ ( P =0.28), phosphorylated‐τ ( P =0.16), Aβ42/Aβ40 ( P =0.14), and phosphorylated‐τ/Aβ42 ( P =0.93). Conclusions: CSF Aβ40 is significantly lower in patients with CAA with prior ICH. Amyloid dysregulation in CAA may follow distinct pathological trajectories depending on previous ICH. CSF Aβ40 shows promise as a biomarker for CAA and merits further studies to explore its prognostic value in disease progression. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04204642.


  • Open Access

    Outcomes in neurointerventional radiology indications and complications (ONIRIC): Anxiety and depressive symptoms, coping strategies, and quality of life before and after elective neuroendovascular treatment

    by Chiara Riccietti, Andrea Giordano, Matteo Milani, Isabella Canavero, Giorgio Boncoraglio, Valentina Caldiera, Giuseppe Ganci, Elisa Ciceri

    Background: Patients undergoing elective endovascular treatment for cerebrovascular diseases (CBVD) may face mental health challenges that impact their quality of life (QoL). However, this issue is still rarely addressed in neuro-endovascular research literature and clinical practice. Our single center ongoing project ONIRIC aims to assess anxiety and depressive symptoms, coping, and QoL in CBVD patients treated via endovascular approaches. Methods: We prospectively enrolled a cohort of patients undergoing elective endovascular procedures over a 6-month period. Patients completed the State-Trait Anxiety Inventory (STAI-S and STAI-T), the Beck Depression Inventory-version II (BDI-II), the Brief Coping Orientation to Problems Experienced Inventory (Brief-Cope), the Euro-QoL 5D-5L, and the World Health Organization Disability Assessment Schedule (WHODAS 2.0) questionnaires at the baseline, and at discharge. Results: We included 25 patients (13 females): mean age 60 ± 12.5 years. There was a significant improvement in state anxiety and depressive symptom scores at discharge: the BDI-II scores significantly differed from the ones at baseline ( p < .01), as well as the STAI-S scores ( p < .01). The coping and QoL scores did not show any changes. Conclusions: To our knowledge, this research represents one of the few prospective studies examining the psychological and neuropsychological outcomes associated with elective neuro-endovascular treatment of CBDV. Despite the small sample size, our preliminary findings, are consistent with recent literature in related fields, contributing valuable insights to the broader understanding of how these factors influence clinical management. Future directions include the collection of follow-up data, essential for deepening our understanding of this complex and sensitive issue.


  • Open Access

    Blurred by a “Puff of Smoke”—A Case-Based Review on the Challenging Recognition of Coexisting CNS Demyelinating Disease and Moyamoya Angiopathy

    by Isabella Canavero, Nicola Rifino, Carlo Antozzi, Valentina Caldiera, Elena Colombo, Tatiana Carrozzini, Giuseppe Ganci, Paolo Ferroli, Francesco Acerbi, Benedetta Storti, et al.

    Moyamoya angiopathy (MMA) is a cerebrovascular disease determining chronic progressive steno-occlusion of the supraclinoid internal carotid arteries and their main branches. The pathogenesis of MMA remains largely unknown. Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system characterized by the progressive accumulation of focal demyelinating lesions, whose pathophysiology has been theorized but still incompletely understood. Beyond misdiagnoses due to mimicking features among the two disorders, MS coexisting with MMA have been previously, rarely, reported. Herein, we present two other cases of patients with MMA with a concomitant, previously missed, diagnosis of MS and discuss their overlapping features as a hint for a potentially shared pathophysiology. The finding of typical angiographic features enables MMA diagnosis, yet it does not allow us to rule out other potentially concomitant disorders affecting the CNS. The association may be easily missed if the clinical/neuroradiological picture is not carefully assessed. Cerebral spinal fluid analysis and spine neuroimaging should be suggested in all MMA patients with atypical MRI lesions.


  • Impact of Conventional Stroke Risk Factors on Early- and Late-Onset Ischemic Stroke: A Mendelian Randomization Study

    by Kevin T.K. Nguyen, Huichun Xu, Brady J. Gaynor, Patrick F. McArdle, Timothy D. O’cOnnor, James A. Perry, Bradford B. Worrall, Rainer Malik, Giorgio B. Boncoraglio, Sally N. Adebamowo, et al.

    BACKGROUND: Stroke incidence is decreasing in older ages but increasing in young adults. These divergent trends are at least partially attributable not only to diverging trends in stroke risk factors but may also be due to differences in the impact of stroke risk factors at different ages. To address this latter possibility, we used Mendelian randomization to assess differences in the association of stroke risk factors between early-onset ischemic stroke ([EOS]; onset 18–59 years) and late-onset ischemic stroke ([LOS]; onset ≥60 years). METHODS: We identified genetic variants from the GWAS Catalog for use as instrumental variables to proxy conventional stroke risk factors and then estimated the effects of these variants on risk factors in younger and older individuals in the UK Biobank. We then used these estimates to estimate the causal effects of stroke risk factors on EOS (n=6728 cases) and LOS (n=9272) cases from SiGN (Stroke Genetic Network) and the EOSC (Early-Onset Stroke Consortium). Lastly, we compared odds ratios between EOS and LOS, stratified by TOAST (Trial of ORG 10172 in Acute Stroke Treatment) subtypes, to determine if differences between estimates could be attributed to differences in stroke subtype distributions. RESULTS: EOS was associated with higher levels of body mass index, blood pressure, type 2 diabetes, and lower levels of HDL (high-density lipoprotein) cholesterol (all P ≤0.002), whereas LOS was associated with higher levels of systolic blood pressure ( P =0.0001). The causal effect of body mass index on stroke was significantly stronger for EOS than for LOS (odds ratio, 1.26 versus 1.03; P =0.008). After the subtype-stratified analysis, the difference in causal effect sizes between EOS and LOS for body mass index diminished and was no longer significant. CONCLUSIONS: These results support a causal relationship between body mass index, blood pressure, type 2 diabetes, and HDL cholesterol levels with EOS and blood pressure levels in LOS. Interventions that target these traits may reduce stroke risk.


  • Open Access

    CSF and Plasma Biomarkers in Patients With Iatrogenic Cerebral Amyloid Angiopathy

    by Giuliana Pollaci, Antonella Potenza, Gemma Gorla, Tatiana Carrozzini, Giulia Marinoni, Carolina De Toma, Isabella Canavero, Nicola Rifino, Giorgio B. Boncoraglio, Jacopo C. Difrancesco, et al.

    Recently, a subset of patients affected by cerebral amyloid angiopathy (CAA) distinguished by atypical juvenile onset and a hypothesized iatrogenic origin (iatrogenic CAA, iCAA) has emerged. β-Amyloid (Aβ) accumulation evidenced by amyloid PET positivity or CSF Aβ decrease was included in the iCAA diagnostic criteria. Conversely, diagnostic criteria for sporadic CAA (sCAA) do not involve biomarker analysis. The aim of this study was to assess CSF and plasma levels of Aβ and tau in iCAA and sCAA cohorts. Patients affected by probable or possible CAA according to established criteria (Boston 2.0) were prospectively recruited at Fondazione IRCCS Carlo Besta and San Gerardo dei Tintori from May 2021 to January 2024. Patients with probable and possible iCAA or sCAA with available plasma and/or CSF samples were included. Clinical and neurologic data were collected, and levels of Aβ40, Aβ42, total tau, and phospho-tau (p-tau) were assessed in CSF and plasma by SiMoA and Lumipulse. 21 patients with iCAA (72% male, mean age at symptom onset 50 years [36-74]) and 32 patients with sCAA (44% male, mean age at symptom onset 68 years [52-80]) were identified. Cognitive impairment and cardiovascular risk factors in the sCAA cohort were more common compared with the iCAA cohort. Patients with sCAA and iCAA showed similar CSF levels for Aβ40 (p = 0.5 [sCAA, 95% CI 2,604-4,228; iCAA, 95% CI 1,958-3,736]), Aβ42 (p = 0.7 [sCAA, 95% CI 88-157; iCAA, 95% CI 83-155]), and total tau (p = 0.08 [sCAA, 95% CI 80-134; iCAA, 95% CI 37-99]). Plasma levels of Aβ40 (p = 0.08, 95% CI 181-222), Aβ42 (p = 0.3, 95% CI 6-8), and total tau (p = 0.4, 95% CI 3-6) were not statistically different in patients with sCAA compared with iCAA ones (Aβ40, 95% CI 153-193; Aβ42, 95% CI 6-7 and total tau, 95% CI 2-4). Despite presenting with a younger age at onset, fewer cardiovascular risk factors, and lower cognitive impairment, patients with iCAA demonstrated Aβ and tau levels comparable with elderly patients with sCAA, supporting a common molecular paradigm between the 2 CAA forms.


  • 18F Flutemetamol-PET Aided Classification of Cerebral Amyloid Angiopathy

    by Michele Romoli, Giulia Marinoni, Luca Tagliabue, Antonella Capozza, Federica Matteucci, Vincenzo Mattone, Marco Longoni, Patrizia Cenni, Maria Ruggiero, Nicola Rifino, et al.

    Cerebral amyloid angiopathy (CAA)-related features on neuroimaging often coexist with signs of arteriolosclerosis-small vessel disease on neuroimaging in people with intracranial hemorrhage (ICH). This study aimed at defining the value of amyloid pathology detected by 18Fflutemetamol PET in reclassification and stratification of risk of bleeding in people with mixed CAA-arteriolosclerosis features. We included consecutive patients admitted to 2 institutions (2018-2023) with spontaneous symptomatic ICH, subarachnoid hemorrhage (SAH), transient focal neurologic episodes (TFNE), or cognitive impairment and MRI showing CAA hallmarks. All patients underwent brain magnetic resonance imaging (MRI) with susceptibility weighted imaging and 18Fflutemetamol PET imaging and were followed up for at least 1 year. We compared cases with CAA and arteriolosclerosis + CAA features and defined long-term outcomes (composite outcome including death, ICH, ischemic stroke, SAH, TFNE) depending on PET status (CAA/amyloid pathology vs arteriolosclerosis-predominant groups). Among 47 patients, according to PET and MRI imaging, 38 patients were reclassified in the CAA/amyloid pathology group and 9 in the arteriolosclerosis-predominant group, with similar cardiovascular risk factors but a significantly higher lobar microbleed burden for the former group. The CAA/amyloid pathology group had higher rates of composite outcome (43.9 vs 11.1 events per 100 patient-year; p = 0.039) and ICH (36.5 vs 5.6 events per 100 patient-years; p = 0.04) compared with the arteriolosclerosis-predominant group. 18FFlutemetamol PET imaging can help in reclassification of mixed arteriolosclerosis + CAA into CAA/amyloid pathology and arteriolosclerosis-predominant, with implications on long-term risk of recurrent events. This study provides Class IV evidence that 18Fflutemetamol PET can distinguish between CAA + arteriolosclerosis and arteriolosclerosis-predominant pathology.


  • Open Access

    The Impact of Conventional Stroke Risk Factors on Early and Late Onset Ischemic Stroke: a Mendelian Randomization Study

    by Kevin Tk Nguyen, Huichun Xu, Brady Gaynor, Sally N. Adebamowo, Patrick F. McArdle, Tim O’connor, Bradford Worrall, Rainer Malik, Giorgio B. Boncoraglio, Ramin Zand, et al.

    Objective Although stroke incidence is decreasing in older ages, it is increasing in young adults. While these divergent trends in stroke incidence are at least partially attributable to diverging prevalence trends in stoke risk factors, age-dependent differences in the impact of stroke risk factors on stroke may also contribute. To address this issue, we utilized Mendelian Randomization (MR) to assess differences in the association of stroke risk factors between early onset ischemic stroke (EOS) and late onset ischemic stroke (LOS). Methods We employed a two-sample MR design with inverse variance weighting as the primary method of analysis. Using large publicly available genome-wide association summary results, we calculated MR estimates for conventional stroke risk factors (body mass index, total, HDL-and LDL-cholesterol, triglycerides, type 2 diabetes, systolic and diastolic blood pressure, and smoking) in EOS cases (onset 18-59 years, n = 6,728) and controls from the Early Onset Stroke Consortium and in LOS cases (onset ≥ 60 years, n = 9,272) and controls from the Stroke Genetics Network. We then compared odds ratios between EOS and LOS, stratified by TOAST subtypes, to determine if any differences observed between effect sizes could be attributed to differences in the distribution of stroke subtypes. Results EOS was significantly associated with all risk factors except for total cholesterol levels, and LOS was associated with all risk factors except for triglyceride and total cholesterol levels. The associations of BMI, DBP, SBP, and HDL-cholesterol were significantly stronger in EOS than LOS (all p < 0.004). The differential distribution of stroke subtypes could not explain the difference in effect size observed between EOS and LOS. Conclusion These results suggest that interventions targeted at lowering body mass index and blood pressure may be particularly important for reducing stroke risk in young adults.

  • Open Access

    Anti-Cyclic Citrullinated Peptide Antibody Index in the Cerebrospinal Fluid for the Diagnosis and Monitoring of Rheumatoid Meningitis

    by Luigi Caputi, Giorgio B. Boncoraglio, Gaetano Bernardi, Emilio Ciusani, Marcello Dantes, Federica de Liso, Alessandra Erbetta, Gianluca Marucci, Caterina Matinato, Elena Corsini

    Rheumatoid meningitis (RM) is a rare but often aggressive neurological complication of rheumatoid arthritis. The diagnosis of RM, besides the clinical, radiological, and laboratory criteria, usually requires a cerebral biopsy. Based on the two cases presented in this paper, we propose a new laboratory marker. Cerebrospinal fluid and serum anti-cyclic citrullinated peptide (CCP) IgG were measured, and the intrathecal synthesis of anti-CCP antibodies (anti-CCP antibody index) was calculated using the hyperbolic function. The anti-CCP antibody index was positive in both cases at first diagnosis and progressively decreased after treatments. Together with clinical and radiological criteria, the calculation of the anti-CCP intrathecal synthesis, more than the simple measurement of serum or cerebrospinal fluid anti-CCP antibody titers, may represent a useful tool for RM diagnosis and, possibly, for treatment response.